Elevated Galectin-3 Levels in the Serum of Patients with Alzheimer's Disease

American Journal of Alzheimer's Disease and other Dementias

Volumn 30, Issue 8, 2015, Pages 729-732

  Wang, Xuexin ^a,b   Zhang, Shuping ^c   Lin, Faliang ^b   Chu, Wenzheng ^b   Yue, Shouwei ^a  

^a SHANDONG UNIVERSITY   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c Yantai Infectious Disease Hospital   (China)

Author keywords

Alzheimer's disease; biomarker; galectin 3; serum; amyloid

Indexed keywords

GALECTIN 3; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MILD COGNITIVE IMPAIRMENT; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; PROTEIN BLOOD LEVEL; BLOOD; MIDDLE AGED; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; FEMALE; GALECTIN 3; HUMANS; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT;

EID: 84947229290     PISSN: 15333175     EISSN: 19382731     Source Type: Journal    
DOI: 10.1177/1533317513495107     Document Type: Article

References (36)

1. Selkoe DJ,. Translating cell biology into therapeutic advances in Alzheimer's disease. Nature. 1999; 399 (6738 suppl): A23-A31.
2. Cotman CW, Su JH,. Mechanisms of neuronal death in Alzheimer's disease. Brain Pathol. 1996; 6 (4): 493-506.
3. Roberson ED, Mucke L,. 100 years and counting: prospects for defeating Alzheimer's disease. Science. 2006; 314 (5800): 781-784.
4. Agrwal N, Sun Q, Wang SY, Wang JL,. Carbohydrate-binding protein 35. I. Properties of the recombinant polypeptide and the individuality of the domains. J Bio Chem. 1993; 268 (20): 14932-14939.
5. Dumic J, Dabelic S, Flögel M., Galectin-3: an open-ended story. Biochim Biophys Acta. 2006; 1760 (4): 616-635.
6. Yang RY, Rabinovich GA, Liu FT,. Galectins: structure, function and therapeutic potential. Expert Rev Mol Med. 2008; 10: e17.
7. Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA., Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci. 2007; 64 (13): 1679-1700.
8. Nangia-Makker P, Honjo Y, Sarvis R, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol. 2000; 156 (3): 899-909.
9. Markowska AI, Liu FT, Panjwani N,. Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med. 2009; 207 (9): 1981-1993.
10. Markowska AI, Jefferies KC, Panjwani N,. Galectin-3 protein modulates cell surface expression and activation of vascular endothelial Growth factor receptor-2 in human endothelial cells. J Biol Chem. 2011; 286 (34): 29913-29921.
11. Taniguchi T, Asano Y, Akamata K, et al. Serum levels of galectin-3: possible association with fibrosis, aberrant angiogenesis, and immune activation in patients with systemic sclerosis. J Rheumatol. 2012; 39 (3): 539-544.
12. Zhou JY, Afjehi-Sadat L, Asress S, et al. Galectin-3 is a candidate biomarker for amyotrophic lateral sclerosis: discovery by a proteomics approach. J Proteome Res. 2010; 9 (10): 5133-5141.
13. Folstein MF, Folstein SE, McHugh PR,. 'Mini mental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12 (3): 189-198.
14. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984; 34 (7): 939-944.
15. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E,. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol. 1999; 56 (3): 303-308.
16. Radosavljevic G, Volarevic V, Jovanovic I, et al. The roles of galectin-3 in autoimmunity and tumor progression. Immunol Res. 2012; 52 (1-2): 100-110.
17. Tam JH, Pasternak SH., Amyloid and Alzheimer's disease: inside and out. Can J Neurol Sci. 2012; 39 (3): 286-298.
18. Reichert F, Rotshenker S,. Galectin-3/MAC-2 in experimental allergic encephalomyelitis. Exp Neurol. 1999; 160 (2): 508-514.
19. Walther M, Kuklinski S, Pesheva P, et al. Galectin-3 is upregulated in microglial cells in response to ischemic brain lesions, but not to facial nerve axotomy. J Neurosci Res. 2000; 61 (4): 430-435.
20. Lerman BJ, Hoffman EP, Sutherland ML, et al. Deletion of galectin-3 exacerbates microglial activation and accelerates disease progression and demise in a SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Brain Behav. 2012; 2 (5): 563-575.
21. Jin JK, Na YJ, Song JH, et al. Galectin-3 expression is correlated with abnormal prion protein accumulation in murine scrapie. Neurosci Lett. 2007; 420 (2): 138-143.
22. Zlokovic BV,. The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron. 2008; 57 (2): 178-201.
23. Filer A, Bik M, Parsonage GN, et al. Galectin 3 induces a distinctive pattern of cytokine and chemokine production in rheumatoid synovial fibroblasts via selective signaling pathways. Arthritis Rheum. 2009; 60 (6): 1604-1614.
24. Kim K, Mayer EP, Nachtigal M,. Galectin-3 expression in macrophages is signaled by Ras/MAP kinase pathway and up-regulated by modified lipoproteins. Biochim Biophys Acta. 2003; 1641 (1): 13-23.
25. Yu F, Finley RL Jr, Raz A, Kim HR,. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem. 2002; 277 (18): 15819-15827.
26. Mok SW, Riemer C, Madela K, et al. Role of galectin-3 in prion infections of the CNS. Biochem. Biophys Res Commun. 2007; 359 (3): 672-678.
27. Boscher C, Dennis JW, Nabi IR,. Glycosylation, galectins and cellular signaling. Curr Opin Cell Biol. 2011; 23 (4): 383-392.
28. Sioud M., New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol. 2011; 73 (2): 79-84.
29. Di Bona D, Rizzo C, Bonaventura G, Candore G, Caruso C,. Association between interleukin-10 polymorphisms and Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis. 2012; 29 (4): 751-759.
30. Narciso MS, Mietto Bde S, Marques SA, et al. Sciatic nerve regeneration is accelerated in galectin-3 knockout mice. Exp Neurol. 2009; 217 (1): 7-15.
31. Jiang HR, Al Rasebi Z, Mensah-Brown E, et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol. 2009; 182 (2): 1167-1173.
32. Mercer N, Ahmed H, McCarthy AD, Etcheverry SB, Vasta GR, Cortizo AM., AGE-R3/galectin-3 expression in osteoblast-like cells: regulation by AGEs. Mol Cell Biochem. 2004; 266 (1-2): 17-24.
33. Thornalley PJ,. Cell activation by glycated proteins. AGE receptors, receptor recognition factors and functional classification of AGEs. Cell Mol Biol (Noisy-le-grand). 1998; 44 (7): 1013-1023.
34. Vasta GR,. Galectins as pattern recognition receptors: structure, function, and evolution. Adv Exp Med Biol. 2012; 946: 21-36.
35. Velasco S, Díez-Revuelta N, Hernández-Iglesias T, et al. Neuronal Galectin-4 is required for axon growth and for the organization of axonal membrane L1 delivery and clustering. J Neurochem. 2013; 125 (1): 49-62.
36. Stancic M, Slijepcevic D, Nomden A, et al. Galectin-4, a novel neuronal regulator of myelination. Glia. 2012; 60 (6): 919-935.